Latest Period
Q4 2025
Security Snapshot
Rani Therapeutics Holdings, Inc. - Class A Common Stock, Par Value $.0001 (RANI) Institutional Ownership
CUSIP: 753018100
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
61
Shares (Excl. Options)
44,799,019
Price
$1.35
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Class A Common Stock, Par Value $.0001
- Symbol
- RANI on Nasdaq
- Shares outstanding
- 98,437,808
- Price per share
- $0.81
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 44,799,019
- Total reported value
- $60,478,537
- % of total 13F portfolios
- 0%
- Share change
- +34,730,267
- Value change
- +$47,505,485
- Number of holders
- 61
- Price from insider filings
- $0.81
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RANI - Rani Therapeutics Holdings, Inc. - Class A Common Stock, Par Value $.0001 is tracked under CUSIP 753018100.
- 61 institutions reported positions in Q4 2025.
- 9 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 61 to 25 between Q4 2025 and Q1 2026.
- Reported value moved from $60,478,537 to $4,562,122.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 61 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 753018100?
CUSIP 753018100 identifies RANI - Rani Therapeutics Holdings, Inc. - Class A Common Stock, Par Value $.0001 in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 753018100:
Significant Owners of Rani Therapeutics Holdings, Inc. - Class A Common Stock, Par Value $.0001 (RANI) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| InCube Labs, L.L.C. | 22% | $13,541,357 | 27,093,552 | MIR A IMRAN | 23 Oct 2025 | |||
| Samsara BioCapital, L.P. | 9.9% | $4,939,262 | 9,882,477 | Srinivas Akkaraju | 23 Oct 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $4,939,262 | 9,882,477 | RA Capital Management, L.P. | 23 Oct 2025 | |||
| Invus Global Management, LLC | 10% | $4,910,990 | 9,825,911 | Raymond Debbane | 16 Oct 2025 | |||
| AWM Investment Company, Inc. | 9.9% | $14,520,561 | 9,745,343 | AWM Investment Company, Inc. | 31 Dec 2025 | |||
| ARMISTICE CAPITAL, LLC | 9.9% | $4,131,600 | 6,260,000 | Armistice Capital, LLC | 30 Jun 2025 | |||
| VANGUARD GROUP INC | 5.2% | $6,897,647 | 5,109,368 | The Vanguard Group | 31 Dec 2025 | |||
| South Cone Investments Limited Partnership | 4.9% | $1,189,121 | 2,379,194 | South Cone Investments Limited Partnership | 20 Oct 2025 | |||
| Orca Capital AG | 4.3% | -56% | $972,105 | -$1,265,416 | 1,891,623 | -57% | Orca Capital AG | 22 Jul 2025 |
As of 31 Dec 2025, 61 institutional investors reported holding 44,799,019 shares of Rani Therapeutics Holdings, Inc. - Class A Common Stock, Par Value $.0001 (RANI). This represents 46% of the company’s total 98,437,808 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Rani Therapeutics Holdings, Inc. - Class A Common Stock, Par Value $.0001 (RANI) together control 45% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 8.6% | 8,500,000 | 1.2% | $11,475,000 | |
| RA CAPITAL MANAGEMENT, L.P. | 8.6% | 8,500,000 | 0.12% | $11,475,000 | |
| AWM Investment Company, Inc. | 6.6% | 6,500,000 | 0.85% | $8,775,000 | |
| SymBiosis Capital Partners, LLC | 6.4% | 6,300,000 | 0% | 8.8% | $8,505,000 |
| VANGUARD GROUP INC | 5.2% | 5,109,368 | +478% | 0% | $6,897,647 |
| Longaeva Partners L.P. | 2.1% | 2,113,435 | 0.34% | $2,853,137 | |
| Siren, L.L.C. | 2% | 2,000,000 | 0.08% | $2,700,000 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.87% | 860,941 | +190% | 0% | $1,162,636 |
| BlackRock, Inc. | 0.54% | 527,712 | +339% | 0% | $712,412 |
| Nan Fung Group Holdings Ltd | 0.5% | 493,584 | 0% | 0.6% | $666,338 |
| 683 Capital Management, LLC | 0.49% | 487,168 | 0.05% | $657,677 | |
| STATE STREET CORP | 0.39% | 387,042 | +520% | 0% | $522,507 |
| Squarepoint Ops LLC | 0.35% | 344,378 | 0% | $464,910 | |
| UNITED SERVICES AUTOMOBILE ASSOCIATION | 0.31% | 302,743 | 0% | 0.03% | $408,703 |
| GOLDMAN SACHS GROUP INC | 0.29% | 285,832 | 0% | $385,873 | |
| KESTRA PRIVATE WEALTH SERVICES, LLC | 0.26% | 254,812 | +13% | 0% | $343,996 |
| NORTHERN TRUST CORP | 0.17% | 170,471 | +76% | 0% | $230,136 |
| MILLENNIUM MANAGEMENT LLC | 0.17% | 163,300 | 0% | $220,455 | |
| UBS Group AG | 0.15% | 151,523 | +119% | 0% | $204,556 |
| CWA Asset Management Group, LLC | 0.15% | 150,000 | 0% | 0.01% | $202,500 |
| Qube Research & Technologies Ltd | 0.15% | 148,226 | 0% | $200,105 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.12% | 114,500 | 0% | $154,575 | |
| FARALLON CAPITAL MANAGEMENT LLC | 0.08% | 78,000 | 0% | $105,300 | |
| OMERS ADMINISTRATION Corp | 0.07% | 69,200 | 0% | $93,420 | |
| KING LUTHER CAPITAL MANAGEMENT CORP | 0.06% | 58,000 | 0% | 0% | $78,300 |
Institutional Holders of Rani Therapeutics Holdings, Inc. - Class A Common Stock, Par Value $.0001 (RANI) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 6,206,458 | $4,562,122 | +$143,254 | $0.73 | 25 |
| 2025 Q4 | 44,799,019 | $60,478,537 | +$47,505,485 | $1.35 | 61 |
| 2025 Q3 | 4,033,213 | $2,015,817 | -$1,258,453 | $0.50 | 36 |
| 2025 Q2 | 6,458,632 | $3,319,783 | +$1,060,111 | $0.51 | 38 |
| 2025 Q1 | 3,609,389 | $4,577,211 | -$332,797 | $1.26 | 38 |
| 2024 Q4 | 3,819,967 | $5,233,595 | -$4,950,047 | $1.37 | 42 |
| 2024 Q3 | 5,911,071 | $12,767,865 | +$5,999,502 | $2.16 | 31 |
| 2024 Q2 | 3,108,475 | $11,809,884 | -$1,252,441 | $3.80 | 33 |
| 2024 Q1 | 3,453,784 | $10,741,251 | +$509,498 | $3.11 | 35 |
| 2023 Q4 | 3,290,303 | $10,923,496 | -$819,783 | $3.32 | 33 |
| 2023 Q3 | 3,207,291 | $6,961,738 | -$151,646 | $2.18 | 32 |
| 2023 Q2 | 3,227,286 | $13,256,941 | +$994,179 | $4.12 | 34 |
| 2023 Q1 | 2,999,366 | $15,475,095 | +$204,634 | $5.16 | 35 |
| 2022 Q4 | 2,885,407 | $17,024,416 | -$1,472,942 | $5.90 | 32 |
| 2022 Q3 | 3,174,344 | $30,405,447 | +$3,581,808 | $9.58 | 30 |
| 2022 Q2 | 2,824,819 | $29,094,000 | +$2,769,956 | $10.33 | 27 |
| 2022 Q1 | 2,556,816 | $34,515,000 | +$17,568,047 | $13.50 | 23 |
| 2021 Q4 | 1,240,919 | $20,288,000 | +$544,189 | $16.35 | 21 |
| 2021 Q3 | 1,097,698 | $19,562,000 | +$19,562,000 | $17.82 | 14 |